What Is the Greatest Regulatory Challenge in the Translation of Biomaterials to the Clinic?

被引：51

作者：

Prestwich, Glenn D. ^{[1
]}

Bhatia, Sangeeta ^{[2
,3
,12
]}

Breuer, Christopher K. ^{[4
]}

Dahl, Shannon L. M. ^{[5
]}

Mason, Chris ^{[6
]}

McFarland, Richard ^{[7
]}

McQuillan, David J. ^{[5
]}

Sackner-Bernstein, Jonathan ^{[8
]}

Schox, Jeffrey ^{[9
,11
]}

Tente, William E. ^{[5
]}

Trounson, Alan ^{[10
]}

Breuer, Christopher K. ^{[4
]}

Trounson, Alan ^{[10
]}

机构：

[1] Univ Utah, Dept Med, Salt Lake City, UT 84108 USA

[2] MIT, Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA

[3] MIT, Inst Med Engn & Sci, Cambridge, MA 02139 USA

[4] Ohio State Univ, Nationwide Childrens Hosp, Ctr Regenerat Med & Cell Based Therapies, Wexner Med Ctr, Columbus, OH 43205 USA

[5] Humacyte, Res Triangle Pk, NC 27709 USA

[6] UCL, Adv Ctr Biochem Engn, London WC1E 6BT, England

[7] US FDA, Ctr Biol Evaluat & Res, Rockville, MD 20852 USA

[8] Neostem, New York, NY 10170 USA

[9] Schox PLC, San Francisco, CA 94107 USA

[10] Calif Inst Regenerat Med, San Francisco, CA 94107 USA

[11] Stanford Law School, Stanford, CA USA

[12] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA

来源：

关键词：

D O I：

10.1126/scitranslmed.3004915

中图分类号：

Q2 [细胞生物学];

学科分类号：

071013 [干细胞生物学];

摘要：

引用

页数：6